Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection
about
Raltegravir cerebrospinal fluid concentrations in HIV-1 infectionAge-related expansion of Tim-3 expressing T cells in vertically HIV-1 infected childrenProgressive multifocal leukoencephalopathy in HIV-1 infection.Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation.HIV infection, inflammation, immunosenescence, and aging.ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.New insights into immune reconstitution inflammatory syndrome of the central nervous system.HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatmentProgressive increase in central nervous system immune activation in untreated primary HIV-1 infectionCellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected SubjectsMinocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot studyCentral nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapyLow levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.The cerebrospinal fluid proteome in HIV infection: change associated with disease severityHIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment.Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.T-cell activation and neurodevelopmental outcomes in perinatally HIV-infected children.Role of immune activation in progression to AIDS.Putamen volume and its clinical and neurological correlates in primary HIV infection.Antiretroviral therapy and central nervous system HIV type 1 infectionInduction of IL-17 and nonclassical T-cell activation by HIV-Tat protein.Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 originMolecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection.How much do antiretroviral drugs penetrate into the central nervous system?HIV and neurocognitive dysfunction.Immune activation in the central nervous system throughout the course of HIV infection.Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls.Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system.Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.Raltegravir resistance in the cerebrospinal fluid.
P2860
Q28476050-53C32FE6-5E50-45C3-AB16-A5ACAA1BA472Q28483967-7ACBEAC9-6535-44FE-84EB-8F976379E0DBQ33506561-D49D74E4-A111-4020-A912-34346AC7220FQ33520347-2AA02123-908B-4DFB-BFA7-C44A3CDFCEA8Q34099733-C84ED1F3-DFF3-45B8-B416-CA694D8A8064Q34150710-309DF2F2-AA20-4B68-8B13-5051DD5A4496Q34202181-0FFC99CD-65E2-42ED-80FE-63C002B3B7A9Q34433828-191AC370-8B15-4D13-805B-33DDE0D00190Q34644242-EDCA7E17-BB91-40A7-B7C0-1422D79A13C3Q34678105-91E3B998-BABE-4496-B2A0-B0B9AD98FA01Q34792090-692A0BFF-D5CE-454B-8E64-B03FF8F33726Q35052651-572DB1A8-427D-45B4-82E1-D76361570D87Q35164448-AD73BDE8-189E-4A51-B372-BE53D202AB03Q35532868-8C86C2B7-ED62-497D-B209-CAD52779FFCDQ35822465-9A45B709-0EDE-4A81-80BD-0639B1D5DB3EQ35965332-4F1DACF2-61EA-410A-9BD0-A85CB2D5CF90Q36009246-5446027A-8EC9-43FB-A5A2-314B2907AD2BQ36060674-F58FB6B7-E42F-45E7-A8CA-AFE3A99B4163Q36222075-78AA4B52-BAE3-4F60-AFD3-C184A05F49A0Q36571165-419F3FB9-6CC5-4B1B-8DB5-A42D5576AEA2Q37047808-0FF6997D-E84F-4F16-85D1-CFA12D815273Q37066982-06CAC795-657F-41A3-BA7D-5A6442D1F93DQ37104090-A3DE8E1D-A590-464E-8536-FA298FFDA22BQ37235279-21D5B02F-F2A2-4BB2-8896-DE5C669D6E77Q37726311-1B2AEB2E-825C-4DDC-B04C-CB222CD3038BQ38003612-ED4CC1BA-FB8D-47CC-976F-7007D7F6F57EQ38122104-6D9C27EE-C423-4DA5-9E6A-5F07F9643FCCQ38694693-D4D37585-41C0-4F5F-92B4-B8BA97B3D501Q38734471-8C5A5AC6-63BD-463F-8BB9-8056B4F07EA6Q41002594-0756945A-93A1-438C-81B2-3CFB829CBC72Q41834830-C36746C7-7CD4-4067-A67B-71C0A791BB80Q43470111-4AD70D7B-A87C-4247-A78B-CAB2C69DB2A9
P2860
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Antiretroviral treatment effec ...... rospinal fluid HIV-1 infection
@ast
Antiretroviral treatment effec ...... rospinal fluid HIV-1 infection
@en
type
label
Antiretroviral treatment effec ...... rospinal fluid HIV-1 infection
@ast
Antiretroviral treatment effec ...... rospinal fluid HIV-1 infection
@en
prefLabel
Antiretroviral treatment effec ...... rospinal fluid HIV-1 infection
@ast
Antiretroviral treatment effec ...... rospinal fluid HIV-1 infection
@en
P2093
P2860
P921
P1476
Antiretroviral treatment effec ...... rospinal fluid HIV-1 infection
@en
P2093
Elizabeth Sinclair
Nicole Lollo
Peter Hunt
Richard W Price
Rollie Ronquillo
Serena Spudich
P2860
P304
P356
10.1097/QAI.0B013E318162754F
P407
P577
2008-04-01T00:00:00Z